Cargando…
Novel Site-Specific Fatty Chain-Modified GLP-1 Receptor Agonist with Potent Antidiabetic Effects
Glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged as treatment options for type 2 diabetes mellitus (T2DM). Here, we designed a high-throughput GLP-1R extracellular domain (ECD)-based system that enabled the screening of high-potency receptor-biased GLP-1R agonists demonstrating new ph...
Autores principales: | Zhong, Xia, Chen, Zhu, Chen, Qiong, Zhao, Wei, Chen, Zhi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412877/ https://www.ncbi.nlm.nih.gov/pubmed/30795583 http://dx.doi.org/10.3390/molecules24040779 |
Ejemplares similares
-
Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010) -
Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
por: Zhang, Hongkai, et al.
Publicado: (2015) -
Novel fatty chain-modified GLP-1R G-protein biased agonist exerts prolonged anti-diabetic effects through targeting receptor binding sites
por: Wang, Maorong, et al.
Publicado: (2020) -
Identification of a Small Molecular Insulin Receptor Agonist With Potent Antidiabetes Activity
por: Qiang, Guifen, et al.
Publicado: (2014) -
Expression and Characterization of a Potent Long-Acting GLP-1 Receptor Agonist, GLP-1-IgG2σ-Fc
por: Yang, Yi, et al.
Publicado: (2016)